REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease

11/09/2025 06:20:19

Main Information	
Primary registry identifying number	Protocol number
LBCTR2019091283	C1701-202
MOH registration number	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	
Type of registration	Type of registration: Justify
Prospective	N/A
Date of registration in national regulatory agency	
Primary sponsor	Primary sponsor: Country of origin
Cyclerion Therapeutics, Inc.	United States of America
Date of registration in primary registry	Date of registration in national regulatory agency
27/03/2021	
Public title	Acronym
A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease	STRONG SCD
Scientific title	Acronym
A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease	STRONG SCD
Brief summary of the study: English	
The primary objective of the C1701-202 STRONG SCD study is to evaluate the safety and tolerability of different dose levels of IW- 1701 compared with placebo when administered daily for approximately 12 weeks to patients with stable sickle cell disease (SCD). Exploratory objectives include evaluation of pharmacokinetic (PK) as well as evaluation of the effect of IW-1701 on symptoms of SCD, health-related quality of life, and biomarkers of pharmacodynamic (PD) activity.	
Brief summary of the study: Arabic	
الهدف الأساسي من دراسة المنجلية المستويات جرعة مختلفة من المنجلية المستقر. تشمل الأهداف الاستكشافية تقييم ١ مقارنة مع الدواء الارضائي عند تناوله يومياً لمدة الحرائك الدوائية W-1701 الحرائك الدوائية (PK) وكذلك تقييم تأثير اء الخلايا المنجلية المستقر ونوعية الحياة المتعلقة بالصحة والمؤشرات الحيوية للنشاط الديناميكي الدوائي	
.(PD)	

Health conditions/problem studied: Specify

Stable sickle cell disease

 \sim

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Interventions: Specify

Eligible patients will be stratified by hydroxyurea (HU) use (yes or no) and randomly assigned in a 3:1 ratio to receive IW-1701 once daily or placebo.

Arm 1: IW-1701 (Olinciguat) -uptitration possible for patients who meet the conditions to begin taking the applicable higher dose. Arm 2: placebo.

Key inclusion and exclusion criteria: Inclusion criteria

1. Patient is ambulatory male or female 16 to 70 years of age at the Screening Visit.

2. Patient has SCD, including HbSS, HbSC, HbSβ0-thalassemia, or HbSβ+-thalassemia, documented in their medical history

3. If patient is on medication(s) for SCD, such as hydroxyurea (HU), are on a stable regimen.

4. Per medical history and/or patient recall, patient has had at least 1 and no more than 10 sickle cell-related pain crises in the 12 months before the Screening Visit and none occurring in the 4 weeks before the Randomization Visit.

5. Women of childbearing potential must have a negative pregnancy test prior to randomization and must agree to use protocol-specified contraception from the Screening Visit through 90 days after the final dose of study drug.

6. Male patients must be surgically sterile by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) or must

agree to use protocol-specified contraception and agree to refrain from sperm donation from the Screening Visit through 90 days after the final dose of study drug.

7. Patient completes daily eDiary entries for at least 10 days during the last 14 days of the Run in Period as assessed at the Randomization Visit.

Key inclusion and exclusion criteria: Gender	Key inclusion and exclusion criteria: Specify gender
Both	
Key inclusion and exclusion criteria: Age minimum	Key inclusion and exclusion criteria: Age maximum

Key inclusion and exclusion criteria: Exclusion criteria

1. Patient requires a program of prescheduled, regularly administered chronic blood transfusion therapy.

2. Patient has been hospitalized for an SCD-related complication in the 4 weeks before the Randomization Visit.

3. Patient has taken opioid(s) >200 morphine mg equivalent/day within the 4 weeks before the Randomization Visit.


4. Patient is taking aspirin ≥325 mg daily, P2Y12 inhibitors, any anticoagulant medication, specific inhibitors of phosphodiesterase 5 (PDE5), nonspecific inhibitors of PDE5, moderate or strong cytochrome P450 3A (CYP3A) inhibitors, any supplements for the treatment of erectile dysfunction, riociguat, or nitrates or nitric oxide donors in any form.

5. Patient has major concurrent illness or medical condition that in the opinion of the Investigator would preclude participation in a clinical study.

Type of study

Interventional

Type of intervention	Type of intervention: Specify type
Pharmaceutical	N/A
Trial scope	Trial scope: Specify scope
Safety	N/A
Study design: Allocation	Study design: Masking
Randomized controlled trial	Blinded (masking used)
Study design: Control	Study phase
Placebo	2
Study design: Purpose	Study design: Specify purpose



Study design: Assignment Study design: Specify assignment Parallal N/A MP has market authorization MP has market authorization: Specify so MP has market authorization: Specify so Ver of authorization Month of authorization Month of authorization W1701/olincipuat. Ver of authorization Vippe of IMP Impact of the second of the s	MINISTRY OF PUBLIC HEALTH	Lebanon Clinical Trials Registry
Paralel NA MA Market authorization NA MA More authorization: Specify More Authorization Authorization More Authorizatin Authorization Authorizatin	Treatment	N/A
No N		
W1701/olinciguat Type of IMP Cell therapy Pharmaceutical class soluble guanylate cyclase (sgc) stimulator Therapeutic indication Stable sickle cell disease Therapeutic bonefit There remains considerable unmet medical need in SCD, not only for treatments that prevent painful circles and other acute complications, but also for treatments that address the daily symptoms of the disease. Study model: Study model: Explain model N/A N/A Study model: Specify model N/A N/A Time perspective: Specify model N/A N/A Time perspective: N/A Time perspective: Specify perspective N/A N/A Target follow-up duration Target follow-up duration: Unit Number of groups/cohorts Biospecimen description Samples with DNA** Optional gencybring testing. If patient agrees, a blood sam mil. Will be collected and stored. The test may help to belied understand how the diseases work, the of Win-XTO1 and and stored. The test may help to belied understand how the diseases work, the of Win-XTO1 and some perspective side effects from UA-YTO1 and some perspectation to perspect don't.		IMP has market authorization: Specify
Outle therapy Pharmaceutical class soluble guanylate cyclase (sgc) stimulator Therapeutic indication Stable sickle cell disease Therapeutic indication indications, but also for treatments that address the daily symptoms of the disease, including chronic pain. Study model Study model: Explain model N/A N/A Study model: Specify model N/A N/A Time perspective: Specify model N/A N/A Target follow-up duration Target follow-up duration: Unit Number of groups/cohorts Singles with DNA** Samples with DNA* Optional genotyping testing. If patient agrees, a blood sam mutual will be collected and stored. The test model shows proves on the body, how mity brook proves on the body, how mity brook prespective on the body, how mity brook prespecti		Year of authorization Month of authorization
Soluble guarylate cyclase (sgc) stimulator Therapeutic indication Stable sickle cell disease Therapeutic benefit There remains considerable unmet medical need in SCD, not only for treatments that prevent painful crises and other acute complications, but also for treatments that address the daily symptoms of the disease, including chronic pain. Study model Study model Study model: Explain model N/A Study model: Specify model N/A Time perspective N/A Time perspective: Specify perspective N/A Traget follow-up duration Target follow-up duration Study model: Stagese, including chronic guary. Study model: Specify model N/A Target follow-up duration Study model: Specify perspective N/A Target follow-up duration Study model: Specify perspective N/A Target follow-up duration Study model: Specify model N/A Study model: Specify perspective N/A Target follow-up duration Study model: Specify perspective Specify perspective N/A Target follow-up duration Study model: Specify perspective		
Therapeutic indication Stable sickle cell disease Therapeutic benefit There remains considerable unmet medical need in SCD, not only for treatments that prevent painful crises and other acute complications, but also for treatments that address the daily symptoms of the disease, including chronic pain. Study model Study model Study model: Explain model N/A N/A Study model: Specify model N/A Time perspective N/A Time perspective: Specify perspective N/A Time perspective: Specify perspective N/A Target follow-up duration Target follow-up duration Study moders Biospecimen retention Samples with DNA** Biospecimen retention Samples with DNA**		
Stable sickle cell disease Therapeutic benefit There remains considerable unmet medical need in SCD, not only for treatments that prevent painful crises and other acute complications, but also for treatments that address the dily symptoms of the disease, including chronic pain. Study model Study model: Explain model N/A N/A Study model: Specify model N/A N/A N/A Study model: Specify model N/A N/A N/A Study model: Specify proces N/A Study model: Specify perspective N/A N/A N/A Time perspective: Specify perspective N/A N/A N/A Target follow-up duration Target follow-up duration: Unit Number of groups/cohorts Biospecimen description Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam m. Will be collected and stored. The test may help to better understand how the diseases and related diseases work, how WV processed by the body. who might benefit from IW-7701 and/or other medications on the body, how IW-processed by the body. who might benefit from IW-7701 and/or other medications on the body, how IW-processed by the body. who might benefit from IW-7701 and/or other medications on the body, body might benefit from IW-7701 and/or other medications on the body, body might benefit from IW-7701 and/or other medications on t		
There remains considerable unmet medical need in SCD, not only for treatments that prevent painful crises and other acute complications, but also for treatments that address the daily symptoms of the disease, including chronic pain. Study model Study model: Explain model N/A N/A Study model: Specify model N/A N/A Time perspective: Explain time perspective: Explain time perspective N/A N/A Time perspective: Specify perspective N/A Time perspective: Specify perspective N/A Target follow-up duration Target follow-up duration: Unit Number of groups/cohorts Biospecimen description Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam mL will be collected and stored. The test may help to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how UV processed by the body, who might benefit from IW-1701 and/or other medications on the body, how UV processed by the body, who might benefit from IW-1701 and/or other medications on the drug but oth people don't.	•	
rises and other acute complications, but also for treatments that address the daily symptoms of the disease, including chronic pain. Study model Study model: Explain model N/A N/A Study model: Specify model N/A Time perspective N/A Time perspective: Specify perspective N/A Target follow-up duration Target follow-up duration: Unit Samples with DNA** Biospecimen retention Samples with DNA** Biospecimen retention Samples with DNA**		
N/A N/A Study model: Specify model N/A Study model: Specify model Time perspective: Explain time perspective N/A N/A Time perspective: Specify perspective N/A Time perspective: Specify perspective N/A Time perspective: Specify perspective N/A Target follow-up duration Target follow-up duration: Unit Number of groups/cohorts Biospecimen description Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam mC will be collected and stored. The test may help to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how IW-processed by the body, who might benefit from IW-1702 and store the body, who might benefit from IW-1703 and store the body, who might benefit from IW-1704 and store the body, who up to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how IW-processed by the body, who might benefit from IW-1702 and store the medications on the body, how IW-processed by the body, who might benefit from IW-1704 and store the medications on the body, how IW-processed by the body, who might benefit from IW-1702 and store the body, who might benefit from IW-1702 and store the body, who might benefit from IW-1702 and store the body, who might benefit from IW-1702 and store the body, who might benefit from IW-1702 and store the body, who might benefit from IW-1702 and store the body who might benefit from IW-1702 and store the body. The store the body is the people don't.	crises and other acute complications, but also for treatments	
Study model: Specify model V/A Time perspective N/A Time perspective: Specify perspective V/A N/A Target follow-up duration Target follow-up duration Number of groups/cohorts Biospecimen retention Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam ML will be collected and stored. The test may help to better understand how the disease and related diseases work, the or (W-1701 and yor other medications on the body, how IW-processed by the body, who might benefit from IW-1701 ard some people have side effects from taking the drug but oth people don't.	-	
N/A N/A Time perspective: Specify perspective N/A Target follow-up duration Target follow-up duration Target follow-up duration Number of groups/cohorts Biospecimen retention Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam L will be collected and stored. The test may help to bette understand how the diseases work, the of IW-1701 and/or other medications on the body, how IW-processed by the body, who might benefit from IW-1701 ar some people have side effects from taking the drug but oth people don't.		
Time perspective: Specify perspective N/A Target follow-up duration Target follow-up duration Number of groups/cohorts Biospecimen retention Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam mL will be collected and stored. The test may help to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how IW-processed by the body, who might benefit from IW-1701 ar some people have side effects from taking the drug but oth people don't.		
N/A Target follow-up duration Target follow-up duration: Unit Number of groups/cohorts Biospecimen retention Biospecimen description Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam mL will be collected and stored. The test may help to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how IW-processed by the body, who might benefit from IW-1701 and some people have side effects from taking the drug but oth people don't.		
Number of groups/cohorts Biospecimen retention Biospecimen description Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam mL will be collected and stored. The test may help to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how IW-processed by the body, who might benefit from IW-1701 ar some people have side effects from taking the drug but oth people don't.		
Biospecimen retention Biospecimen description Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam mL will be collected and stored. The test may help to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how IW-processed by the body, who might benefit from IW-1701 ar some people have side effects from taking the drug but oth people don't.	Target follow-up duration	Target follow-up duration: Unit
Samples with DNA** Optional genotyping testing. If patient agrees, a blood sam mL will be collected and stored. The test may help to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how IW- processed by the body, who might benefit from IW-1701 ar some people have side effects from taking the drug but oth people don't.	Number of groups/cohorts	
mL will be collected and stored. The test may help to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how IW- processed by the body, who might benefit from IW-1701 ar some people have side effects from taking the drug but oth people don't.	Biospecimen retention	Biospecimen description
Target sample size Actual enrollment target size	Samples with DNA**	Optional genotyping testing. If patient agrees, a blood sampl mL will be collected and stored. The test may help to better understand how the disease and related diseases work, the of IW-1701 and/or other medications on the body, how IW-17 processed by the body, who might benefit from IW-1701 and some people have side effects from taking the drug but other people don't.
	Target sample size	Actual enrollment target size

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Date of first enrollment: Type Anticipated	Date of first enrollment: Date 18/11/2019
Date of study closure: Type	Date of study closure: Date
Anticipated	20/01/2021
Recruitment status	Recruitment status: Specify
Complete	
Date of completion	
22/07/2020	
IPD sharing statement plan	IPD sharing statement description
No	Not applicable
Additional data URL	
https://www.clinicaltrials.gov/ct2/show/NCT03285178	
Admin comments	
Trial status	
Approved	

Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
ClinicalTrials.gov	NCT03285178	

Sources of Monetary or Material Support	
Name	
Cyclerion Therapeutics, Inc.	

Secondary Sponsors

Name

None



Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Dr. Gino Girardi	100 Brandywine Boulevard	United States of America	+1 919 418 5164	gino.girardi@syn eoshealth.com	Syneos Health (previsouly INC Research)
Scientific	Dr. Wissam Houhou	Ghassan Hammoud Street, Saida	Lebanon	+961 70 874 770	dr_houhou_wiss am@hotmail.com	Hammoud Hospital University Medical Center
Scientific	Dr. Adlette Inati	El Maarad Street, Tripoli	Lebanon	+961 3 228 033	adlette.inati@lau. edu.lb	Nini Hospital
Scientific	Dr. Ali Taher	Cairo Street, Beirut	Lebanon	+961 3 755 669	ataher@aub.edu. lb	American University of Beirut Medical Center

Centers/Hospitals Involved in the Study				
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval	
Hammoud Hospital University Medical Center	Dr. Wissam Houhou	Hematology and Oncology	Approved	
Nini Hospital	Dr. Adlette Inati	Pediatric Hematology Oncology	Approved	

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hammoud Hospital University Medical Center	16/09/2019	Ghada Aoun	medical@hammoudhospital.org	+961 7 723 111 Ext 1956
Nini Hospital	25/09/2019	Sarah Kharsa	sarah.kharsa@hopitalnini.com	+961 6 431 400 Ext 452

Countries of Recruitment Name Lebanon United Kingdom United States of America

REPUBLIC OF LEBANON Ministry of Public Health Lebanon Clinical Trials Registry

Health Conditions or Problems Studied			
Condition Code Keyword			
sickle cell disease	Sickle-cell disorders (D57)	Sickle Cell Disease (SCD)	

Interventions			
Intervention	Description	Keyword	
Arm 1	Placebo	Placebo	
Arm 2	IW-1701	olinciguat	

Primary Outcomes		
Name	Time Points	Measure
Safety and tolerability	12 weeks	Incidence, frequency, and severity of TEAEs and study drug-related TEAEs

Key Secondary Outcomes		
Name	Time Points	Measure
Hemodynamic Parameters	12 weeks	blood pressure and pulse
Pain Crisis Paramaters	12 weeks	Time to first pain crisis, proportion and frequency of pain crisis
Biomarkers	12 weeks	Biomarker concentration changes
Pharmacokinetic	12 weeks	Plasma concentrations
Patient-reported Outcomes	12 weeks	Patient Questionnaires





Trial Results Summary results Study results globally Date of posting of results summaries Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files